A methionine-free diet associated with nitrosourea treatment down-regulates methylguanine-DNA methyl transferase activity in patients with metastatic cancer

Anticancer Research

Volumn 27, Issue 4 C, 2007, Pages 2779-2783

  Thivat, Emilie ^a,b   Durando, Xavier ^a,b   Demidem, Aicha ^b   Farges, Marie Chantal ^c   Rapp, Maryse ^b   Cellarier, Eric ^a   Guenin, Samuel ^b   D'Incan, Michel ^d   Vasson, Marie Paule ^c   Chollet, Philippe ^a,b  

^a CENTRE JEAN PERRIN   (France)

^b INSERM   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

^d HÔTEL DIEU   (France)

Author keywords

CENU; Glioma; Melanoma; Methionine free diet; Methylguanine DNA methyl transferase; MGMT; PBMC

Indexed keywords

CYSTEMUSTINE; ENZYME; METHIONINE; METHYLGUANINE DNA METHYL TRANSFERASE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET; DOWN REGULATION; ENZYME ACTIVITY; GLIOMA; HUMAN; HUMAN CELL; LEUKOPENIA; MELANOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DIET; DOWN-REGULATION; HUMANS; LEUKOCYTES, MONONUCLEAR; MELANOMA; METHIONINE; NITROSOUREA COMPOUNDS; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; OLIGODENDROGLIOMA;

EID: 34547746978     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, Namer M, Bonneterre J, Kerbrat P, Bonerandi JJ et al: Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer 66: 1873-1878, 1990.
2. Galanis E and Buckner J: Chemotherapy for high-grade gliomas. Br J Cancer 82: 1371-1380, 2000.
3. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, Nova P, Aglione S, Taillibert S and Khayat D: Metastatic melanoma: chemotherapy. Semin Oncol 29: 427-445, 2002.
4. Brandes AA, Tosoni A, Amista P, Nicolardi L, Grosso D, Berti F and Ermani M: How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 63: 1281-1284, 2004.
5. 2: a phase II trial. Anticancer Drugs 16: 1003-1007, 2005.
6. Durando X, Thivat E, Roche H, Bay JO, Lemaire JJ, Verrelle P, Lentz MA, Chazal J, Cure H and Chollet P: Cystemustine in recurrent high grade glioma. J Neurooncol 79: 33-37, 2006.
7. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 50: 6119-6129, 1990.
8. 6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity. Clin Cancer Res 4: 463-468, 1998.
9. Belanich M, Pastor M, Randall T, Guerra D, Kibitel J, Alas L, Li B, Citron M, Wasserman P, White A, Eyre H, Jaeckle K, Schulman S, Rector D, Prados M, Coons S, Shapiro W and Yarosh D: Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 56: 783-788, 1996.
10. 6 methylguanine-DNA methyl-transferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study. J Clin Oncol 16: 3310-3315, 1998.
11. 6-methylguanine-DNA methyltransferase levels and clinical response induced by chloroethylnitrosourea therapy in glioma patients. Can J Neurol Sci 26: 104-109, 1999.
12. 14C-methyl)-L-methionine uptake in rat brain tumors before and after treatment with the protein synthesis inhibitor cycloheximide. J Neurooncol 15: 229-233, 1993.
13. Guo HY, Herrera H, Groce A and Hoffman RM: Expression of the biochemical defect of methionine dependence in fresh patient tumors in primary histoculture. Cancer Res 53: 2479-2483, 1993.
14. Hoffman RM: Altered methionine metabolism, DNA methylation and oncogene expression in carcinogenesis. A review and synthesis. Biochim Biophys Acta 738: 49-87, 1984.
15. Hoshiya Y, Guo H, Kubota T, Inada T, Asanuma F, Yamada Y, Koh J, Kitajima M and Hoffman RM: Human tumors are methionine dependent in vivo. Anticancer Res 15: 717-718, 1995.
16. Breillout F, Antoine E and Poupon MF: Methionine dependency of malignant tumors: a possible approach for therapy. J Natl Cancer Inst 82: 1628-1632, 1990.
17. Cellarier E, Durando X, Vasson MP, Farges MC, Demiden A, Maurizis JC, Madelmont JC and Chollet P: Methionine dependency and cancer treatment. Cancer Treat Rev 29: 489-499, 2003.
18. Kokkinakis DM, Hoffman RM, Frenkel EP, Wick JB, Han Q, Xu M, Tan Y and Schold SC: Synergy between methionine stress and chemotherapy in the treatment of brain tumor xenografts in athymic mice. Cancer Res 61: 4017-4023, 2001.
19. Poirson-Bichat F, Goncalves RA, Miccoli L, Dutrillaux B and Poupon MF: Methionine depletion enhances the antitumoral efficacy of cytotoxic agents in drug-resistant human tumor xenografts. Clin Cancer Res 6: 643-653, 2000.
20. 6-methylguanine-DNA methyltransferase by methionine in human tumour cells. Br J Cancer 75: 779-788, 1997.
21. Morvan D, Papon J, Madelmont JC and Demidem A: Methionine deprivation potentiates the effect of cystemustine treatment on B16 melanoma tumors in syngeneic recipients. Proceedings AACR 43: 771, 2002.
22. 6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer 67: 216-221, 1993.
23. 6-alkylguanine-DNA-alkyltransferase in lymphocytes and melanoma of patients treated with CB 10-277, a new DTIC analogue. Cancer Chemother Pharmacol 31: 240-246, 1992.
24. 6-alkylguanine- DNA alkyltransferase activity in circulating blood mononuclear cells of healthy human subjects. Int J Cancer 91: 60-66, 2001.
25. Minet-Quinard R, Van Praagh I, Kwiatkowski F, Beaujon G, Feillel V, Beaufrere B, Bargnoux PJ, Cynober L and Vasson MP: Pre- and postoperative aminoacidemia in breast cancer: a study vs. matched healthy subjects. Cancer Invest 22: 203-210, 2004.
26. WHO handbook for reprinting results of Cancer Treatment. WHO offset publication No 48 Neoplasma 20: 37-46, 1990.
27. 6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J Biol Chem 269: 17228-17237, 1994.
28. Bearzatto A, Szadkowski M, Macpherson P, Jiricny J and Karran P: Epigenetic regulation of the MGMT and hMSH6 DNA repair genes in cells resistant to methylating agents. Cancer Res 60: 3262-3270, 2000.
29. Christmann M, Pick M, Lage H, Schadendorf D and Kaina B: Acquired resistance of melanoma cells to the antineoplastic agent fotemustine is caused by reactivation of the DNA repair gene MGMT. Int J Cancer 92: 123-129, 2001.
30. Yang Z, Wang J, Lu Q, Xu J, Kobayashi Y, Takakura T, Takimoto A, Yoshioka T, Lian C, Chen C, Zhang D, Zhang Y, Li S, Sun X, Tan Y, Yagi S, Frenkel EP and Hoffman RM: PEGylation confers greatly extended half-life and attenuated immunogenicity to recombinant methioninase in primates. Cancer Res 64: 6673-6678, 2004.
31. Yang Z, Wang J, Yoshioka T, Li B, Lu Q, Li S, Sun X, Tan Y, Yagi S, Frenkel EP and Hoffman RM: Pharmacokinetics, methionine depletion, and antigenicity of recombinant methioninase in primates. Clin Cancer Res 10: 2131-2138, 2004.
32. Sun X, Yang Z, Li S, Tan Y, Zhang N, Wang X, Yagi S, Yoshioka T, Takimoto A, Mitsushima K, Suginaka A, Frenkel EP and Hoffman RM: In vivo efficacy of recombinant methioninase is enhanced by the combination of polyethylene glycol conjugation and pyridoxal 5′-phosphate supplementation. Cancer Res 63: 8377-8383, 2003.